Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II drugs for Colorectal Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sirexatamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sirexatamab overview

Sirexatamab (DKN-01, LY-2812176) is under development for the treatment of bile duct cancer, esophageal cancer, fallopian tube cancer, adenocarcinoma of the gastroesophageal junction, epithelial ovarian cancer, peritoneal cancer, endometrial cancer, carcinosarcoma (uterine cancer), gallbladder cancer, colorectal cancer, advanced gynecological cancers and extrahepatic bile duct cancer. The drug candidate is administered intravenously. It is a monoclonal antibody targeting dickkopf homolog 1 (Dkk-1). The drug candidate was also under development for the treatment of relapsed or refractory multiple myeloma, metastatic castration-resistant prostate cancer and non-small cell lung cancer.

Leap Therapeutics overview

Leap Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with different types of cancer. The company’s pipeline products include DKN-01. DKN-1 is a monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, prostate cancer and gynecologic cancer. The company has an agreement with BeiGene Ltd for development rights and commercialization of DKN-01 in Australia, Asia (excluding Japan) and New Zealand. Leap Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Sirexatamab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.